BDBM147461 US8957103, C

SMILES: COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCCOC(=O)C(N)CC(C)C)c2ccccc12

InChI Key: InChIKey=MHEYLSXQBQEYPZ-UHFFFAOYSA-N

Data: 3 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 3 hits for monomerid = 147461   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Vascular endothelial growth factor receptor 2 (Homo sapiens (Human))	BDBM147461 (US8957103, C) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCCOC(=O)C(N)CC(C)C)c2ccccc12 |t:13| Show InChI InChI=1S/C30H35N3O7/c1-17(2)13-21(31)30(36)40-12-8-11-33-16-20(19-9-6-7-10-22(19)33)26-25(28(34)32-29(26)35)18-14-23(37-3)27(39-5)24(15-18)38-4/h6-7,9-10,14-17,21H,8,11-13,31H2,1-5H3,(H,32,34,35)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem Similars	US Patent	n/a	n/a	>1.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg—Universitat Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US8957103 (2015) BindingDB Entry DOI: 10.7270/Q2SJ1J99
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 beta (Homo sapiens (Human))	BDBM147461 (US8957103, C) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCCOC(=O)C(N)CC(C)C)c2ccccc12 |t:13| Show InChI InChI=1S/C30H35N3O7/c1-17(2)13-21(31)30(36)40-12-8-11-33-16-20(19-9-6-7-10-22(19)33)26-25(28(34)32-29(26)35)18-14-23(37-3)27(39-5)24(15-18)38-4/h6-7,9-10,14-17,21H,8,11-13,31H2,1-5H3,(H,32,34,35)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem Similars	US Patent	n/a	n/a	134	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg—Universitat Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US8957103 (2015) BindingDB Entry DOI: 10.7270/Q2SJ1J99
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens (Human))	BDBM147461 (US8957103, C) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCCOC(=O)C(N)CC(C)C)c2ccccc12 |t:13| Show InChI InChI=1S/C30H35N3O7/c1-17(2)13-21(31)30(36)40-12-8-11-33-16-20(19-9-6-7-10-22(19)33)26-25(28(34)32-29(26)35)18-14-23(37-3)27(39-5)24(15-18)38-4/h6-7,9-10,14-17,21H,8,11-13,31H2,1-5H3,(H,32,34,35)	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem Similars	US Patent	n/a	n/a	480	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg—Universitat Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US8957103 (2015) BindingDB Entry DOI: 10.7270/Q2SJ1J99
					More data for this Ligand-Target Pair